title: Changes in bone mineral metabolism parameters, including FGF23, after discontinuing cinacalcet at kidney transplantation.
abstract: Little is known about the effects of the administration of cinacalcet in dialytic patients who are scheduled for kidney transplantation, and in particular about the changes in FGF23 and other mineral metabolism parameters after surgery compared with recipients not on cinacalcet at kidney transplantation. We performed a prospective observational cohort study with recruitment of consecutive kidney transplant recipients at our institution. Patients were classified according to whether they were under treatment with cinacalcet before transplantation. Bone mineral metabolism parameters, including C-terminal FGF23, were measured at baseline, on day 15, and at 1, 3, and 6 months after transplantation. In previously cinacalcet-treated patients, cinacalcet therapy was discontinued on the day of surgery and was not restarted after transplantation. A total of 48 kidney transplant recipients, 20 on cinacalcet at surgery and 28 cinacalcet non-treated patients, completed the follow-up. Serum phosphate declined significantly in the first 15 days after transplantation with no differences between the two groups, whereas cinacalcet-treated patients showed higher FGF23 levels, although not significant. After transplantation, PTH and serum calcium were significantly higher in cinacalcet-treated patients. We conclude that patients receiving cinacalcet on dialysis presented similar serum phosphate levels but higher PTH and serum calcium levels during the initial six months after kidney transplantation than cinacalcet non-treated patients. The group previously treated with cinacalcet before transplantation showed higher FGF23 levels without significant differences, so further studies should investigate its relevance in the management of these patients.
authors.affiliation: Nephrology and Renal Transplant Department, Hospital Clinic, Barcelona, Spain.
authors.forename: Xoana
authors.initials: X
authors.lastname: Barros
authors.forename: David
authors.initials: D
authors.lastname: Fuster
authors.forename: Raphael
authors.initials: R
authors.lastname: Paschoalin
authors.forename: Federico
authors.initials: F
authors.lastname: Oppenheimer
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
authors.forename: Pilar
authors.initials: P
authors.lastname: Perlaza
authors.forename: Francesca
authors.initials: F
authors.lastname: Pons
authors.forename: Jose V
authors.initials: JV
authors.lastname: Torregrosa
mesh_terms: D000328:Adult; D000368:Aged; D001842:Bone and Bones / Q000378:metabolism*; D057966:Calcimimetic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002118:Calcium / Q000097:blood*; D000069449:Cinacalcet / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D006934:Hypercalcemia / Q000097:blood*; D017674:Hypophosphatemia / Q000097:blood*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood*; D011446:Prospective Studies
chemical_list: D057966:Calcimimetic Agents; C000717427:FGF23 protein, human; D010710:Phosphates; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D002118:Calcium; D000069449:Cinacalcet